Cargando…
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
A large number of adenoviral agents are being developed for the treatment of cancer. However, the treatment-related death of a patient with ornithine transcarbamylase deficiency following adenovirus administration by hepatic artery has led to serious concerns regarding the safety of intravascular ad...
Autores principales: | Reid, Tony, Warren, Robert, Kirn, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091735/ https://www.ncbi.nlm.nih.gov/pubmed/12522437 http://dx.doi.org/10.1038/sj.cgt.7700539 |
Ejemplares similares
-
Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver
por: Au, T, et al.
Publicado: (2006) -
Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents
por: Del Papa, Joshua, et al.
Publicado: (2017) -
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine
por: Nyendak, Melissa, et al.
Publicado: (2016) -
Discrimination of Kawasaki disease with concomitant adenoviral detection differentiating from isolated adenoviral infection
por: Kim, Jong Han, et al.
Publicado: (2018) -
Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound
por: Murphy, Gavin J, et al.
Publicado: (2004)